News
CLLS
1.470
+2.80%
0.040
Weekly Report: what happened at CLLS last week (0914-0918)?
Weekly Report · 6d ago
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
Barchart · 09/19 18:31
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Barchart · 09/17 10:00
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Barchart · 09/16 16:50
Cellectis: An 'All Or Nothing' Pivot To In-Vivo Gene Editing Is Worth Monitoring
Seeking Alpha · 09/16 14:11
This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Benzinga · 09/16 14:10
Starbucks initiated, Expedia downgraded: Wall Street’s top analyst calls
TipRanks · 09/16 13:45
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 09/16 13:10
Cellectis Cut to Underweight From Overweight by Barclays
Dow Jones · 09/16 12:59
Cellectis Price Target Cut to $1.30/Share From $9.00 by Barclays
Dow Jones · 09/16 12:59
Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3
Benzinga · 09/16 12:50
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 09/16 12:06
Cellectis downgraded to Underweight from Overweight at Barclays
TipRanks · 09/16 09:00
Cellectis falls as Citizens downgrades on pivot to genetic medicines
Seeking Alpha · 09/15 17:33
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Benzinga · 09/15 14:04
Ulta Beauty, Etsy upgraded: Wall Street’s top analyst calls
TipRanks · 09/15 13:41
Cellectis Price Target Cut to $3.00/Share From $4.00 by Wells Fargo
Dow Jones · 09/15 12:53
Cellectis Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 09/15 12:53
Cellectis Price Target Cut to $8.00/Share From $10.00 by Baird
Dow Jones · 09/15 12:52
Cellectis Is Maintained at Outperform by Baird
Dow Jones · 09/15 12:52
More
Webull provides a variety of real-time CLLS stock news. You can receive the latest news about Cellectis through multiple platforms. This information may help you make smarter investment decisions.
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.